No Data
Haseko, Daiwa House, ETC (additional) Rating
Upgraded - Bullish Code Stock Name Brokerage Firm Previous Change After -------------------------------------------------------- <8056> BIPROGY City "3" "2" Downgraded - Bearish Code Stock Name Brokerage Firm Previous Change After -------------------------------------------------------- <3659> Nexon Nomura "Buy" "
Rating information (Target Price change - Part 2) = KOKUSA, Koss Corp, etc.
◎ Mizuho Securities (three tiers: Buy > Hold > underperform) KOKUSAI <6525.T> -- "Buy" → "Buy", 3,600 yen → 4,600 yen Hotonikusu <6965.T> -- "Buy" → "Buy", 3,400 yen → 3,300 yen ZOZO <3092.T> -- "Hold" → "Hold", 4,400 yen → 4,800 yen ◎ Morgan Stanley MUFG Securities (three tiers: Overweight > Equal Weight > Underweight) Cosmo Energy Holdings <5021.T> --
Recruit Holdings has revised its 2025/3 operating profit upward to 488 billion yen from 442.7 billion yen.
Recruit Holdings <6098> announced a revision of its financial estimates for the fiscal year ending in March 2025. Revenue has been revised upward from 3 trillion 468.7 billion yen to 3 trillion 560 billion yen, and operating profit has been revised upward from 442.7 billion yen to 488 billion yen. The HR Technology business, centered around the US job search site "Indeed," is performing well, contributing to increased revenue per paid job advertisement. Matching & solutions such as the real estate site "SUUMO" and the beauty reservation site "Hot Pepper View Inc" are also contributing.
Key points of the PTS on the 12th = Rakuten Bank, GMO R&A, Sumitomo Construction.
▽ Rakuten Bank <5838.T>, Earnings Reports and Financial Estimates revisions ▽ GMO R&A <3695.T>, Earnings Reports and Financial Estimates and Dividends forecast revisions as well as the introduction of a Shareholder benefit system ▽ Mizuho Construction <1821.T>, Earnings Reports and Financial Estimates revisions ▽ Japan Electrical Construction <1950.T>, Dividend increase and share buyback ▽ JGC HD <1963.T>, Earnings Reports and Financial Estimates revisions ▽ Sasmmed <4263.T>, achievement of milestones related to a joint research and development and sales agreement with Aska Pharmaceutical ▽ SIGG <
ZOZO Sees FY Net Y45.20B
Zozo: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated) (completion of mid-term review by certified public accountants, etc.)
Momentum Trader OP : Strong close with vol today 20/8